�鶹Ů��

Philips Respironics has agreed to a $479 million partial settlement on claims over flaws in the company’s breathing machines that spewed gases and flecks of foam into the airways of consumers and that spawned recalls involving millions of the devices, lawyers for plaintiffs in the lawsuit announced on Thursday. (Jewett, 9/7)

Treatment with the diabetes and weight loss drug semaglutide may allow people newly diagnosed with Type 1 diabetes to dramatically cut back or even completely stop insulin injections, a very small study published Wednesday suggests. ... Experts not involved with the study called the results exciting, but stressed that much more research is needed.

Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy. The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis BioMedical Research. (Wosen, 9/8)

On a Friday afternoon in July, as many New Yorkers fled the scorching city streets, a couple of dozen out-of-towners descended on Times Square. They came bearing gold letter balloons spelling out LFVN, the stock symbol for LifeVantage, the company they’d come to promote, and foam cutouts of its navy blue supplement bottles. LifeVantage’s chief executive officer, Steve Fife, rang the Nasdaq exchange’s closing bell, a celebration of the Utah-based company’s new products and rewards programs. Displayed on the side of the seven-story Nasdaq building were advertisements promoting the company’s dietary supplements and their power to “optimize health.” (Gellman, 9/8)

There’s a diversity problem in cancer clinical trials, and few know this better than Stephanie Walker. When she was diagnosed with stage 4 metastatic breast cancer, Walker said there was no one to help her figure out the system, not even a nurse or patient navigator. (Balthazar, 9/7)

The Biden administration’s recommendation last week for the Drug Enforcement Administration (DEA) to reschedule marijuana marked one of its most significant steps related to the president’s ambitious campaign promise to decriminalize cannabis use. But advocates and policy experts say rescheduling marijuana under the Controlled Substances Act (CSA) does not address the plethora of racial justice issues caused by current cannabis laws. (Choi and Daniels, 9/8)